Risk of major adverse cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: emulated target trials using routine, de-identified data from South Africa

Dorward J., Masombuka X., Lewis L., Pastellides C., van der Molen J., Asare K., Tlhaku K., Brown JA., Bottomley C., Jacobs D., Collie S., Garrett N.

DOI

10.1101/2025.03.07.25323562

Type

Preprint

Publication Date

10/03/2025

Permalink Original publication